Clinical Trial Update: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update indicates that an early-phase window-of-opportunity study of ulixertinib for MAPK-activated gliomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gliomas

Drugs mentioned

• Ulixertinib (BVD-523) (ulixertinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gliomas | EARLY_Phase 1 | Status: RECRUITING